Can Esketamine Become a Viable Alternative for Treating Treatment-Resistant Depression in Ecuador?
European Psychiatry April 1, 2025 E. Pazmiño, K. Armas
IntroductionTreatment-resistant Depression (TRD) nowadays it is consider a public health problem. Studies had demonstrate that TRD has higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality. Esketamine, the S-enantiomer of ketamine, has been recently approved...